Development of autoimmune hemolytic anemia after BNT162b2 mRNA COVID-19 vaccination

OKUNO Shingo, HASHIMOTO Ken, SHIMIZU Rie, TAKAGI Erina, KAJIGUCHI Tomohiro

doi:10.11406/rinketsu.62.1510

<p>A 75-year-old woman with a history of postoperative chemotherapy for lung adenocarcinoma and a history of Helicobacter pylori eradication for idiopathic thrombocytopenic purpura (ITP) was admitted to the department of hematology and oncology for the treatment of anemia 2 weeks after BNT162b2 mRNA COVID-19 vaccination. Her blood examination revealed direct and indirect Coombs test-positive hemolytic anemia and elevation of serum LDH and indirect bilirubin levels. No obvious trigger other than BNT162b2 mRNA COVID-19 vaccination was found. She was diagnosed with autoimmune hemolytic anemia (AIHA), and oral prednisolone therapy was administered. The anemia improved soon after the administration of prednisolone. Although vaccination is considered to be very important for suppressing the spread of COVID-19, there have been reports of increasing risk of ITP development and deterioration caused by BNT162b2 mRNA COVID-19 vaccination. Because the number of vaccinated people is increasing rapidly, hematologists must be vigilant to the development of AIHA after BNT162b2 mRNA COVID-19 vaccination although case reports of this phenomenon have been very rare thus far.</p>

Development of autoimmune hemolytic anemia after BNT162b2 mRNA COVID-19 vaccination

Bibliographic Information

Search this article

Description

Journal

Citations (1)*help

Keywords

Details 詳細情報について

Export

Report a problem